2023

20/12/2023

PromarkerD to be available in Chile in expanded deal with Omics Global Solutions

23/11/2023

AGM Chairman’s Address and Investor Presentation

22/11/2023

US Medicare confirms reimbursement price for PromarkerD

09/11/2023

Proteomics International receives $1.85 million in R&D tax incentive

30/10/2023

Investor Presentation – Non-deal Roadshow

26/10/2023

Quarterly Activities Report September 2023 – Appendix 4C

23/10/2023

Notice of Annual General Meeting 2023

02/10/2023

Webinar and Q&A on PromarkerD US CMS price & TGA decision

29/09/2023

PromarkerD US CMS price & TGA decision

08/09/2023

Oseophageal cancer test presented

04/09/2023

OxiDx technology secures Japan patent

22/08/2023

Corporate Governance Statement and Appendix 4G

22/08/2023

Annual Report 2023 to shareholders

22/08/2023

Preliminary Final Report

14/08/2023

Exercise of Options

14/08/2023

Application for quotation of securities – PIQ

25/07/2023

Proteomics presents at 17th Bioshares Biotech Summit

24/07/2023

Quarterly Activities Report and Year Ahead

20/07/2023

Promarker pipeline – Oesophageal cancer diagnostic test update

10/05/2023

Proteomics International & Sonic Healthcare USA sign exclusive licence agreement to market PromarkerD in the US

05/05/2023

New diagnostic blood test showcased at world’s premier endometriosis conference

03/05/2023

PromarkerD is a potential diagnostic tool to demonstrate the benefits of canagliflozin in diabetic kidney disease

27/04/2023

Quarterly update March 2023 – Appendix 4C

26/04/2023

Clinical Advisory Board expanded to support PromarkerD USA and global rollout

17/04/2023

Proteomics renews its ISO 13485 certification & ISO 17025 accreditation

24/03/2023

Results of a novel blood test for Endometriosis were presented at international conference

01/03/2023

US update: PromarkerD licensing negotiations

15/02/2023

Distribution agreement for PromarkerD in Britain extended

02/02/2023

Investor Presentation – Euroz Hartleys Healthcare Forum

31/01/2023

Letter of intent with Sonic Healthcare USA extended

31/01/2023

Quarterly Update December 2022 – Appendix 4C

09/01/2023

Letter of intent with Sonic Healthcare USA extended

03/01/2023

CPT PLA Reimbursement Code Approved in US for PromarkerD

Subscribe

  • This field is for validation purposes and should be left unchanged.